GlassScriptPhysician profile
Heidi E Godoy
NPI 1427211366
$1,127,784.60
in general payments reported to CMS, 2019-2025
25 companies · $191K in 2025
The $191K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140K · 2020: $89K · 2021: $114K · 2022: $166K · 2023: $171K · 2024: $257K · 2025: $191K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $289K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $125K · Travel and Lodging: $108K · Consulting Fee: $83K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $288,992.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $125,381.25 |
| Travel and Lodging | $108,145.44 |
| Consulting Fee | $82,960.15 |
| Food and Beverage | $13,602.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391,053.71 | 2020-2025 | Jemperli, Zejula |
| Eisai INC. | $277,346.53 | 2022-2025 | |
| Tesaro, INC. | $127,672.51 | 2019 | |
| Abbvie INC. | $121,326.90 | 2019-2025 | |
| Genmab U.S., INC. | $109,551.62 | 2022-2025 | Tivdak, Epkinly |
| Immunogen, INC. | $32,743.21 | 2023-2024 | Elahere, Elahere |
| Biom'Up France Sas | $23,069.23 | 2020-2021 | |
| Intuitive Surgical, INC. | $17,627.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $6,523.75 | 2022-2025 | Lynparza |
| Dilon Technologies, INC. | $6,199.90 | 2022-2025 | Hemoblast Bellows |
| Biom'Up Sa | $6,182.44 | 2019 | |
| Seagen INC. | $2,362.50 | 2022 | |
| Clovis Oncology, INC. | $2,280.24 | 2019-2022 | |
| Kerecis Limited | $1,142.56 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Pfizer INC. | $1,113.60 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wright Medical Technology, INC. | $668.59 | 2019 | |
| Merck Sharp & Dohme LLC | $382.76 | 2019-2025 | Lynparza |
| Myriad Genetic Laboratories, INC. | $222.40 | 2023-2024 | Precisetumor, Myrisk |
| Daiichi Sankyo INC. | $77.88 | 2023 | Enhertu |
| Ethicon US, LLC | $71.78 | 2019 | |
| Sumitomo Pharma America, INC. | $47.06 | 2025 | Gemtesa |
| Stryker Corporation | $44.83 | 2022 | |
| Astellas Pharma US INC | $29.80 | 2024 | Veozah |
| Lilly USA, LLC | $23.66 | 2024 | Mounjaro, Zepbound |
| Dynasplint Systems INC. | $19.22 | 2025 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Godoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.